19 related articles for article (PubMed ID: 25119006)
1. Gamma Irradiation Upregulates B-cell Translocation Gene 2 to Attenuate Cell Proliferation of Lung Cancer Cells Through the JNK and NF-κB Pathways.
Wang P; Cai Y; Lin D; Jiang Y
Oncol Res; 2017 Aug; 25(7):1199-1205. PubMed ID: 28251885
[TBL] [Abstract][Full Text] [Related]
2. Selected immunohistochemical features of conventional renal cell carcinomas coexpressing P53 and MDM2.
Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Chłosta P; Szopiński T; Okoń K
Pol J Pathol; 2014 Jun; 65(2):113-9. PubMed ID: 25119170
[TBL] [Abstract][Full Text] [Related]
3. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
4. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Suster D; Ronen S; Peterson JF; Mackinnon AC; Hes O; Suster S; Lin DI
Hum Pathol; 2019 May; 87():28-36. PubMed ID: 30825458
[TBL] [Abstract][Full Text] [Related]
6. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
7. Selected morphologic features influencing the prognosis of conventional renal cell carcinomas co-expressing P53 and MDM2.
Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Szopiński T; Chłosta P; Okoń K
Pol J Pathol; 2014 Mar; 65(1):29-33. PubMed ID: 25119006
[TBL] [Abstract][Full Text] [Related]
8. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
9. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]